Given that taxanes have been reported to have antiangiogenic activity by inhibiting vascular endothelial proliferation, motility and invasiveness in vitro, and tumor angiogenesis in vivo[61], combination of taxanes and antiangiogenic therapies targeting VEGF or VEGFR2 may provide superior efficacy, particularly in patients with squamous cell carcinoma of the lung. The gene discussed is VEGFA; the disease is squamous cell lung carcinoma.